IP Library › Granted Patent US 12,534,754
Granted Patent B2
US 12,534,754 · App. 17/858,984 · Granted Jan 27, 2026

Attenuators

Inventors: Joanne M. Yeakley (Encinitas, CA); Bruce Seligmann (Tucson, CA); Joel McComb (Rancho Santa Fe, CA)
Assignee: BioSpyder Technologies, Inc.
C12Q1/6813
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,534,754
App. No.
17/858,984
Granted
Jan 27, 2026
Kind
B2
Abstract

Methods for detecting nucleic acid sequences, where attenuator oligonucleotides are provided to reduce the number of detection products resulting from highly abundant sequences.

Claims (27)

1 . A method for detecting a plurality of target nucleic acid sequences of interest in samples, wherein each target sequence has an upstream region (UR) and a downstream region (DR), the method comprising:

(a) contacting the sample with a pool of detector oligos comprising, for each target sequence,

(1) a downstream detector oligo (DDO) comprising a portion complementary to the downstream region of the target sequence (DR′), and

(2) an upstream detector oligo (UDO) comprising a portion complementary to the upstream region of the target sequence (UR′),

wherein, for a predetermined set of potentially high abundance target sequences (HATs) in the sample, also contacting the sample with

(3) an attenuator oligonucleotide that comprises a portion at least partially complementary to at least one of the downstream or upstream regions of a HAT, wherein the portion is of sufficient length to specifically bind to the downstream or upstream region of the HAT, and further comprises a nonextendable or nonligatable blocking group, or a nonamplifiable segment, and

(b) ligating a downstream detector oligo for a target sequence to a corresponding upstream detector oligo if both are hybridized to the downstream and upstream regions of a target sequence in the sample; and

(c) labeling the product of step (b) in a sample with a barcode sequence;

whereby the number of HAT products to be detected is attenuated and the barcoded ligation product indicates the presence of the target sequence and identifies the sample.

2 . The method of claim 1 , wherein at least one of the detector oligos is detectably labeled.

3 . The method of claim 1 , wherein at least one of the detector oligos has a barcode sequence.

4 . The method of claim 1 , further comprising repeating step (c) on multiple samples from step (b).

5 . The method of claim 1 , further comprising the step of amplifying the ligated oligos.

6 . The method of claim 5 , wherein the amplified products incorporate a barcode sequence that is specific to the sample.

7 . The method of claim 1 , wherein an attenuator further has a portion that is complementary to a region adjacent to the downstream or upstream region of a HAT.

8 . The method of claim 1 , wherein an attenuator has a portion that is complementary to at least a portion of the downstream region of a HAT and another portion that is complementary to at least a portion of the upstream region of the HAT.

9 . The method of claim 1 , wherein an attenuator is complementary to a UR, a DR, or both.

10 . The method of claim 1 , wherein the attenuator oligonucleotide comprises a nonextendable blocking group.

11 . The method of claim 1 , wherein the attenuator oligonucleotide comprises a nonligatable blocking group.

12 . The method of claim 1 , wherein the blocking group is a nonhybridizing portion.

13 . The method of claim 1 , wherein the attenuator oligonucleotide comprises a nonamplifiable segment.

14 . The method of claim 13 , wherein the nonamplifiable segment comprises a nonamplifiable tail.

15 . The method of claim 13 , wherein the attenuator oligonucleotide is not phosphorylated.

16 . The method of claim 1 , wherein the attenuator oligonucleotide is phosphorylated.

17 . The method of claim 16 , wherein the attenuator oligonucleotide is circularizing.

18 . The method of claim 1 , wherein the attenuator oligonucleotide specifically binds to a downstream region of an exon junction of a target sequence.

19 . The method of claim 1 , wherein the attenuator oligonucleotide specifically binds to an upstream region of an exon junction of a target sequence.

Assignments (3)
LICENSE Recorded Dec 5, 2025
From: BIOSPYDER TECHNOLOGIES, INC.
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 073870/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: YEAKLEY, JOANNE M.; SELIGMANN, BRUCE; MCCOMB, JOEL
To: BIOSPYDER TECHNOLOGIES, INC.
Reel/Frame 068013/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: SHEPARD, PETER J.; YEAKLEY, JOANNE M.; SELIGMANN, BRUCE
To: BIOSPYDER TECHNOLOGIES, INC.
Reel/Frame 068013/0708 →
Continuity (7)
Continuation 17188319 · Mar 1, 2021
Continuation In Part 15938178 · Mar 28, 2018
Division 14480525 · Sep 8, 2014
Continuation 15920381 · Mar 13, 2018
Division 14595069 · Jan 12, 2015
Continuation In Part 14480525 · Sep 8, 2014
Related Publication 20240229105A1 · Jul 11, 2024
References Cited (1)
Larman et al., “Sensitive, multiplex and direct quantification of RNA sequences using a modified RASL assay,” Nucleic Acids Res. 2014, 42:9146-9157, with 7 pages of Supplementary Materials, published online Jul. 25, 201… [cited by examiner]